|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatocellular carcinoma in viral and autoimmune liver diseases:Role of CD4+CD25+Foxp3+regulatory T cells in the immune microenvironment显示文摘More than 90%of cases of hepatocellular carcinoma(HCC)occurs in patients with cirrhosis,of which hepatitis B virus and hepatitis C virus are the leading causes,while the tumor less frequently arises in autoimmune liver diseases.Advances in understanding tumor immunity have led to a major shift in the treatment of HCC,with the emergence of immunotherapy where therapeutic agents are used to target immune cells rather than cancer cells.Regulatory T cells(Tregs)are the most abundant suppressive cells in the tumor microenvironment and their presence has been correlated with tumor progression,invasiveness,as well as metastasis.Tregs are characterized by the expression of the transcription factor Foxp3 and various mechanisms ranging from cell-to-cell contact to secretion of inhibitory molecules have been implicated in their function.Notably,Tregs amply express checkpoint molecules such as cytotoxic T lymphocyte-associated antigen 4 and programmed cell-death 1 receptor and therefore represent a direct target of immune checkpoint inhibitor(ICI)immunotherapy.Taking into consideration the critical role of Tregs in maintenance of immune homeostasis as well as avoidance of autoimmunity,it is plausible that targeting of Tregs by ICI immunotherapy results in the development of immune-related adverse events(irAEs).Since the use of ICI becomes common in oncology,with an increasing number of new ICI currently under clinical trials for cancer treatment,the occurrence of irAEs is expected to dramatically rise.Herein,we review the current literature focusing on the role of Tregs in HCC evolution taking into account their opposite etiological function in viral and autoimmune chronic liver disease,and we discuss their involvement in irAEs due to the new immunotherapies. | Alessandro Granito Luigi Muratori Claudine Lalanne Chiara Quarneti Silvia Ferri Marcello Guidi Marco Lenzi Paolo Muratori | 2021 | World Journal of Gastroenterology2021，27，22： | 11 |
| 2 | Large regenerative nodules in a patient with Budd-Chiari syndrome after TIPS positioning while on the liver transplantation list diagnosed by Gd-EOB-DTPA MRI显示文摘BACKGROUND:Large regenerative nodules (LRNs) are hyperplastic benign nodules most commonly associated with Budd-Chiari syndrome (BCS),caused by outflow obstruction of the hepatic veins or vena cava.To our knowledge,no cases of LRNs arising in BCS after transjugular intrahepatic portosystemic shunt (TIPS) positioning and detected by GdEOB-DTPA MRI have been reported in the literature.METHODS:A 58-year-old woman with BCS,on the liver transplantation (LT) list,underwent a follow-up enhanced MRI.Two years earlier,a TIPS had been placed.In 2008,recurrent hepaticoencephalopathy resistant to medical treatment fulfilled the LT criteria for BCS treated with TIPS and the patient was therefore added to the LT list.CT performed before TIPS had not detected any hepatic lesions.CT performed six months after TIPS showed its complete patency but documented two indeterminate hypervascular liver lesions.RESULTS:MRI performed with Gd-EOB-DTPA revealed additional hypervascular lesions with uptake and retention of the medium in the hepatobiliary phase,thus reflecting a benign behavior of hepatocellular composition.These MRI features were related to LRNs as confirmed by histopathologic analysis.CONCLUSIONS:Gd-EOB-DTPA-enhanced MRI is potentially superior to standard imaging using gadolinium chelates or spiral CT,especially for the differential diagnosis of hypervascular lesions.Gd-EOB-DTPA MRI may become the imaging method of choice for evaluating LT list patients with BCS after TIPS placement. | Matteo Renzulli Vincenzo Lucidi Cristina Mosconi Chiara Quarneti Emanuela Giampalma Rita Golfieri | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，4： | 5 |
| 3 | Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases显示文摘 | Cumali Efe Staffan Wahlin Ersan Ozaslan Alexandra Heurgue Berlot Tugrul Purnak Luigi Muratori Chiara Quarneti Osman Yüksel Gérard Thiéfin Paolo Muratori | 2012 | European Journal of Gastroenterology & Hepatology2012，，5： | 2 |
| 4 | Antinuclear antibodies as ancillary markers in primary biliary cirrhosis显示文摘 | Granito A1 Muratori P Quarneti C | 2012 | Expert Rev Mol Diagn2012，12，1： | 1 |
| 5 | Auto- immune hepatitis in Italy:the Bologna experience显示文摘 | Muratori P Granito A Quarneti C | 2009 | J Hepatol2009，50，6： | 1 |
| 6 | Autoimmune hepatitis in Italy: The Bologna experience显示文摘 | Paolo Muratori Alessandro Granito Chiara Quarneti Silvia Ferri Rita Menichella Fabio Cassani Georgios Pappas Francesco B. Bianchi Marco Lenzi Luigi Muratori | 2009 | Journal of Hepatology2009，，6： | 1 |
| 7 | Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases显示文摘 | Cumali Efe Staffan Wahlin Ersan Ozaslan Alexandra Heurgue Berlot Tugrul Purnak Luigi Muratori Chiara Quarneti Osman Yüksel Gérard Thiéfin Paolo Muratori | 2012 | European Journal of Gastroenterology & Hepatology2012，，5： | 1 |
| 8 | Antinuclear an- tibodies as ancillary markers in primary biliary cirrhosis 显示文摘 | Granito A Muratori P Quarneti C | 2012 | Expert Rev Mol Diagn2012，12，1： | 1 |
| 9 | Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation显示文摘AIM:To evaluate the effect of long-term treatment with leukocyte natural-interferon(ln-α-IFN)plus ribavirin(RBV).METHODS:Forty-six patients with hepatitis C virus(HCV)recurrence received 3 MU three times a week of ln-α-IFN plus RBV for 1 mo;then,patients with good tolerability(n=30)were switched to daily IFN administration,while the remaining were treated with the same schedule.Patients have been treated for 12 mo after viral clearance while non-responders(NR)entered in the longterm treatment group.Liver biopsies were planned at baseline,1 year after sustained virological response(SVR)and at 36 mo after start of therapy in NR.MedCalc software package was used for statistical analysis.RESULTS:About 16.7%of genotype 1-4 and 70%of genotype 2-3 patients achieved SVR.Nine patients withdrew therapy because of non-tolerance or noncompliance.A significant improvement in serum biochemistry and histological activity was observed in all SVR patients and long-term treated;100%of patients with SVR achieved a histological response(fibrosis stabilization or improvement)with a significant reduction in mean staging value(from 2.1 to 1.0;P=0.0031);histological response was observed in 84%of long-term treated patients compared to 57%of drop-out.Six patients died during the entire study period(follow-up 40.6±7.7 mo);of them,5 presented with severe HCV recurrence on enrollment.Diabetes(OR=0.38,95%CI:0.08-0.59,P=0.01),leukopenia(OR=0.54,95%CI:0.03-0.57,P=0.03)and severe HCV recurrence(OR=0.51,95%CI:0.25-0.69,P=0.0003)were variables associated to survival.Long-term treatment was well tolerated;no patients developed rejection or autoimmune disease.CONCLUSION:Long-term treatment improves histology in SVR patients and slows disease progression also in NR,leading to a reduction in liver decompensation,graft failure and liver-related death. | Mariarosa Tamè Federica Buonfiglioli Massimo Del Gaudio Andrea Lisotti Paolo Cecinato Antonio Colecchia Francesco Azzaroli Antonietta D’Errico Rosario Arena Claudio Calvanese Chiara Quarneti Giorgio Ballardini Antonio Daniele Pinna Giuseppe Mazzella | 2013 | World Journal of Gastroenterology2013，19，32： | 0 |
| 10 | Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence显示文摘Hepatocellular carcinoma(HCC)is rarely associated with autoimmune paraneoplastic syndromes.We report a case of anti-transcriptional intermediary factor-1 gamma(TIF1-γ)-positive dermatomyositis(DM)as clinical presentation of HCC recurrence in a 72-year-old male patient admitted to our hospital due to fatigue,myalgia,and typical skin rash.His medical history was notable for hepatitis C-related cirrhosis,successful treatment with direct-acting antiviral agents,and previously efficacious treatment of HCC.Laboratory testing showed significant rhabdomyolysis with antiTIF1-γantibodies at high titer,and DM was diagnosed.After a careful diagnostic workup,HCC recurrence was diagnosed.After first-line corticosteroid treatment,azathioprine and intravenous immunoglobulin treatments were administered;unfortunately,he mounted only partial response.Owing to the compromised performance status,no HCC treatment was feasible,and,according to international guidelines,he received only best supportive care.Here,we discuss the diagnostic,prognostic,and pathogenic roles of anti-TIF1-γantibodies associated with paraneoplastic DM and the scant literature data on its occurrence in HCC patients.Considering the TIF1 gene family’s established role in oncogenesis,we also review the role of TIF1-γas a tumor-related neoantigen,leading to the development of clinically overt antiTIF1-γantibodies-positive DM. | Marco Ferronato Claudine Lalanne Chiara Quarneti Michele Cevolani Chiara Ricci Alessandro Granito Luigi Muratori Marco Lenzi | 2023 | Journal of Clinical and Translational Hepatology2023，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员